港股异动 | 再鼎医药(09688)再涨超5% ZL-1310拟纳入突破性疗法有望成为SCLC治疗领域突破性疗法

智通财经02-13

智通财经APP获悉，再鼎医药(09688)再涨超5%，截至发稿，涨5.1%，报15.26港元，成交额8197.41万港元。消息面上，2月9日，再鼎医药的注射用ZL-1310拟纳入突破性疗法，拟用于一线含铂治疗期间或治疗后出现疾病进展的广泛期小细胞肺癌(ES-SCLC)患者。ZL-1310在早期临床研究中展现出的疗效数据非常突出，尤其是在二线及以上治疗和脑转移患者中均显示出高缓解率，使其有潜力成为...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2611937183?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-02-13 10:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2611937183","market":"fut","top_or_hot":-1,"title":"港股异动 | 再鼎医药(09688)再涨超5% ZL-1310拟纳入突破性疗法 有望成为SCLC治疗领域突破性疗法","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，再鼎医药(09688)再涨超5%，截至发稿，涨5.1%，报15.26港元，成交额8197.41万港元。消息面上，2月9日，再鼎医药的注射用ZL-1310拟纳入突破性疗法，拟用于一线含铂治疗期间或治疗后出现疾病进展的广泛期小细胞肺癌(ES-SCLC)患者。ZL-1310在早期临床研究中展现出的疗效数据非常突出，尤其是在二线及以上治疗和脑转移患者中均显示出高缓解率，使其有潜力成为...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1405021.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 再鼎医药(09688)再涨超5% ZL-1310拟纳入突破性疗法 有望成为SCLC治疗领域突破性疗法</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 再鼎医药(09688)再涨超5% ZL-1310拟纳入突破性疗法 有望成为SCLC治疗领域突破性疗法\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-13 10:52 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1405021.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，再鼎医药(09688)再涨超5%，截至发稿，涨5.1%，报15.26港元，成交额8197.41万港元。消息面上，2月9日，再鼎医药的注射用ZL-1310拟纳入突破性疗法，拟用于一线含铂治疗期间或治疗后出现疾病进展的广泛期小细胞肺癌(ES-SCLC)患者。ZL-1310在早期临床研究中展现出的疗效数据非常突出，尤其是在二线及以上治疗和脑转移患者中均显示出高缓解率，使其有潜力成为...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1405021.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VT","symbol_name":"世界全股市ETF-Vanguard","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1405021.html","article_id":"2611937183","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2611937183","pubTimestamp":1770951178,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，再鼎医药再涨超5%，截至发稿，涨5.1%，报15.26港元，成交额8197.41万港元。消息面上，2月9日，再鼎医药的注射用ZL-1310拟纳入突破性疗法，拟用于一线含铂治疗期间或治疗后出现疾病进展的广泛期小细胞肺癌患者。ZL-1310在早期临床研究中展现出的疗效数据非常突出，尤其是在二线及以上治疗和脑转移患者中均显示出高缓解率，使其有潜力成为SCLC治疗领域的突破性疗法。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"VT":"世界全股市ETF-Vanguard","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","09688":"再鼎医药","BK4531":"中概回港概念","BK4585":"ETF&股票定投概念","BK4588":"碎股","BK4526":"热门中概股","BK1588":"回港中概股","BK1161":"生物科技","ZLAB":"再鼎医药","BK1574":"生物医药B类股","VXUS":"国际股票ETF-Vanguard","BK4548":"巴美列捷福持仓","BK4139":"生物科技"},"translate_title":"Changes in Hong Kong stocks | Zai Lab (09688) rose more than 5% ZL-1310 is planned to be included in breakthrough therapy and is expected to become a breakthrough therapy in the field of SCLC treatment","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ZLAB":1.5,"VXUS":1.5,"VT":1.5,"09688":1.5},"content_text":"智通财经APP获悉，再鼎医药(09688)再涨超5%，截至发稿，涨5.1%，报15.26港元，成交额8197.41万港元。消息面上，2月9日，再鼎医药的注射用ZL-1310拟纳入突破性疗法，拟用于一线含铂治疗期间或治疗后出现疾病进展的广泛期小细胞肺癌(ES-SCLC)患者。ZL-1310在早期临床研究中展现出的疗效数据非常突出，尤其是在二线及以上治疗和脑转移患者中均显示出高缓解率，使其有潜力成为SCLC治疗领域的突破性疗法。海通国际此前发布研报称，公司一方面通过引进并商业化海外产品获取稳定收入，另一方面依托跨境平台推动创新管线全球开发。核心管线中，靶向DLL3的ADC药物Zocilurtatug计划在2026年底前启动三项注册临床，覆盖小细胞肺癌和神经内分泌癌。此外，公司还拥有多款具备差异化潜力的早期全球资产，如ZL-1503、ZL-6201等，共同支撑其长期价值创造。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2611937183","isCrawlerRequest":true}

港股异动 | 再鼎医药(09688)再涨超5% ZL-1310拟纳入突破性疗法 有望成为SCLC治疗领域突破性疗法

精彩评论

港股异动 | 再鼎医药(09688)再涨超5% ZL-1310拟纳入突破性疗法有望成为SCLC治疗领域突破性疗法